+

WO2007048361A1 - Méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension - Google Patents

Méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension Download PDF

Info

Publication number
WO2007048361A1
WO2007048361A1 PCT/CZ2006/000073 CZ2006000073W WO2007048361A1 WO 2007048361 A1 WO2007048361 A1 WO 2007048361A1 CZ 2006000073 W CZ2006000073 W CZ 2006000073W WO 2007048361 A1 WO2007048361 A1 WO 2007048361A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
mixture
solvent
solvents
crystallization
Prior art date
Application number
PCT/CZ2006/000073
Other languages
English (en)
Inventor
Stanislav Radl
Jan Stach
Original Assignee
Zentiva, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, A.S. filed Critical Zentiva, A.S.
Publication of WO2007048361A1 publication Critical patent/WO2007048361A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention concerns an improved method of removing the triphenyhnethane protecting group from precursors of antihypertensive drugs of general formula I
  • angiotensin II antagonists which are used therapeutically as cardiovascular system drugs, mainly for the control of high blood pressure.
  • This group includes important drugs, such as losartan (Cozaar R ), irbesartan (Avapro R ), or valsartan (Diovan R ).
  • the substances according to the invention are biologically inactive; the active substance is formed first by the metabolic degradation of group R.
  • These precursors have better bioavailability and are used therapeutically instead of the active substance itself.
  • B represents a heterocyclic unit with one or two 5- or 6-membered rings at least one of which contains two nitrogen heteroatoms, and R is a metabolically degradable group.
  • the method consists in the reaction of the substance of formula I with water in the presence of an organic solvent which is completely, or at least partially, miscible with water, leading to the formation of the substance of formula II.
  • R usually such substituents are selected that contain in their structures acetals of C 2 to C 8 aliphatic or aromatic aldehydes, ketals of C 3 to C 10 aliphatic or aromatic ketones, esters of carbonic acid with Ci to Cio aliphatic alcohols, or cyclic 5-, 6-, or 7-membered esters of carbonic acid.
  • tritylated precursors of antihypertensive drugs include for example 5 -methyl-2-oxo- 1 , 3 -dioxol-4-ylmethyl-4-( 1 -hydroxy- 1 -methylethyl)-2-propyl- 1 - [2 ' - (iV-triphenylmethyltetrazol-5-yl)biphenyl-4-yl-methyl]imidazole-5-carboxylate (trityl olmesartan medoxomil) of formula III
  • triphenylmethane protecting group from substituted tetrazoles is usually carried out by the action of a mineral acid in a suitable solvent, for example dioxane (US patent 5,399,578).
  • a suitable solvent for example dioxane
  • this method is suitable only for substances not containing in their molecules other groups sensitive to acids, which is the case of the above-mentioned compounds.
  • Another method is based on the methano lysis of the triphenylmethane protecting group, where methyltriphenyl ether and free tetrazole are formed during the boil (WO 2005/021535).
  • the starting trityl candesartan cilexetil of formula IV whose synthesis is described in the original patent (US patent 5,196,444) and which is currently already commercially available, is, in methanol using hydrochloric acid, converted into candesartan cilexetil of formula VI.
  • the method described in the original patent (US patent 5,196,444) has a very low yield and the product has to be purified chromato graphically.
  • the Takeda company has improved this key step by using anhydrous hydrogen chloride in methanol (US patent 5,763,619), wherein the amount of decomposition products is lower and the yield is higher.
  • Disadvantages of the aforementioned methods include a high content of impurities associated with the decomposition of the ester function, the use of strongly corrosive acids, and also the need to process the reaction mixture using complicated extractions. Such a production is then not economical.
  • the subject-matter of the invention consists in an improved method of removing the triphenylmethane protecting group from precursors of antihypertensive drugs having a labile, metabolically degradable group.
  • the essence of the invention consists in the surprising finding that the removal of the triphenylmethane protecting group from the aforementioned substances can be carried out using only water in a suitable solvent without using acids, which results in a significantly lower decomposition of the ester functions of these substances.
  • R is a metabolically degradable group
  • B is a heterocyclic moiety with one or two 5- or 6-membered rings at least one of which contains two nitrogen heteroatoms
  • the reaction is advantageously carried out at a temperature of 30 to 100 °C for 1 to 48 hours, preferably 5 to 20 hours.
  • the reaction can be carried out using water in solvents which are miscible with water.
  • the reaction proceeds faster in dipolar aprotic solvents such as dimethylsulfoxide, dimethylformamide, acetonitrile, or acetone. It proceeds very slowly for example in tetrahydrofuran and dioxane.
  • the reaction is carried out preferably at the boil of the mixture of solvents. The amount of water is usually one to five fold with respect to the weight of the starting substance.
  • the solvent is advantageously selected from a group of polar aprotic solvents or a mixture of polar and nonpolar aprotic solvents.
  • Polar aprotic solvents are advantageously selected from a group comprising C 3 to C 5 ketones, preferably acetone or ethyl methyl ketone, acetonitrile, and C 1 to C 4 acetates, preferably ethyl or isopropyl acetate.
  • Nonpolar aprotic solvents that can advantageously be used include C 5 to C 8 aromatic or cyclic compounds, both carbocyclic and heterocyclic, preferably toluene, cyclohexane or tetrahydrofuran.
  • the resulting trityl alcohol of formula IX is removed by crystallization from a solvent, or a mixture of solvents, in which candesartan cilexetil of formula IV is insoluble, whereas the trityl alcohol soluble.
  • trityl alcohol of formula IX is removed by stirring with solvents or their mixtures in which candesartan cilexetil of formula IV is insoluble, whereas the trityl alcohol soluble, at a temperature of 5 to 50 0 C, preferably at 15 to 30 0 C.
  • Suitable mixed solvents are mixtures of solvents in which candesartan cilexetil dissolves easily with solvents in which this substance dissolves only partially.
  • Suitable solvents in which candesartan cilexetil dissolves easily include C 1 -C 4 alcohols, preferably methanol, ethanol or 2-propanol, C 1 -C 2 halogenated solvents, preferably dichloromethane or chloroform, C 1 -C 4 aliphatic ketones, preferably acetone or 2-butanone, dialkyl ethers with Ci- C 4 alkyls, preferably diisopropyl ether and methyl t-butyl ether, and esters OfCi-C 5 carboxylic acids with Ci-C 4 aliphatic alcohols, preferably methyl acetate, ethyl acetate, isopropyl acetate or ethyl propionate.
  • Suitable solvents in which candesartan cilexetil dissolves only partially include cycloalkanes, for example cyclohexane, C 5 -C 8 aliphatic hydrocarbons, for example pentane, hexane, heptane or isooctane.
  • cycloalkanes for example cyclohexane, C 5 -C 8 aliphatic hydrocarbons, for example pentane, hexane, heptane or isooctane.
  • Trityl alcohol of formula IX can advantageously be removed from the crude product by crystallization or stirring out of cyclohexane or toluene.
  • Ethyl ester 3 (20 g) was dissolved in THF (80 ml) at 50 0 C (60 minutes). After cooling to 25 0 C, a 40% solution of KOH (10 ml) was added, and the mixture was stirred vigorously for 24 h. After adding ethyl acetate (10 ml), the solution cleared up (neutralization). After concentrating to ca. 40 ml in vacuo, the mixture was diluted with ethyl acetate (100 ml), and solid NaCl (20 g) was added. After separating the phases, the organic layer was filtered and concentrated to ca. 30 ml in vacuo. Methyl ethyl ketone (50 ml) was added to this solution, the mixture was concentrated to 30 ml in vacuo for the subsequent reaction.
  • a solution of potassium salt 4 in methyl ethyl ketone from the preceding experiment (ca. 20 g of the salt) was diluted with methyl ethyl ketone (290 ml), and, after adding potassium iodide (2 g) and 4-chloromethyl-5-methyl-l,3-dioxol-2-one (7 g), the mixture was stirred at 50 0 C for 7.5 h. After the reaction was completed, the mixture was filtered, and the filtrate was washed with methyl ethyl ketone (3 x 50 ml). After concentrating to ca. 160 ml in vacuo, ethanol (250 ml) was added, and the reaction mixture was again concentrated to ca. 300 ml in vacuo.
  • the starting substance (III; 10 g) was dissolved in acetone (50 ml), and, after adding water (25 g), the mixture was heated to a mild boil for 14 h. After evaporating acetone and adding ethyl acetate (50 ml), water was separated, and the organic layer was again washed with water (10 ml). The extract was concentrated and evaporated with toluene (50 ml) once more, the residue was dissolved in ethyl acetate (20 ml) and toluene (20 ml).
  • Example 16 The crystals obtained by the method described in Example 14 were stirred with acetonitrile (15 ml) at room temperature for 4 hours. A product having HPLC purity of 99.3 % was obtained.
  • Example 16 The crystals obtained by the method described in Example 14 were stirred with acetonitrile (15 ml) at room temperature for 4 hours. A product having HPLC purity of 99.3 % was obtained.
  • Example 14 The crystals obtained by the method described in Example 14 were purified by crystallization from acetonitrile (15 ml) and then by stirring at room temperature for 4 hours. A product having HPLC purity of 99.7 % was obtained.
  • Example 14 The crystals obtained by the method described in Example 14 were purified by crystallization from the mixture toluene/2-methoxyethane and then by stirring at 10 0 C for 6 hours. A product having HPLC purity of 99.4 % was obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension de formule générale I, où R représente un groupement métaboliquement dégradable, B représente un groupement hétérocyclique comprenant un ou deux cycles à 5 ou 6 chaînons dont l'un au moins contient deux hétéroatomes d'azote, ladite méthode impliquant la réaction du composé de formule I avec de l'eau en présence d'un solvant partiellement ou entièrement miscible avec l'eau.
PCT/CZ2006/000073 2005-10-27 2006-10-25 Méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension WO2007048361A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20050679A CZ299902B6 (cs) 2005-10-27 2005-10-27 Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
CZPV2005-679 2005-10-27

Publications (1)

Publication Number Publication Date
WO2007048361A1 true WO2007048361A1 (fr) 2007-05-03

Family

ID=37685893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2006/000073 WO2007048361A1 (fr) 2005-10-27 2006-10-25 Méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension

Country Status (2)

Country Link
CZ (1) CZ299902B6 (fr)
WO (1) WO2007048361A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026255A1 (fr) * 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'un intermédiaire d'olmésartan médoxomil
WO2010134052A1 (fr) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Procédé pour la préparation d'olmésartan médoxomil
WO2011007368A2 (fr) 2009-07-14 2011-01-20 Cadila Healthcare Limited Procédé amélioré de préparation d'olmésartan
KR20110109638A (ko) * 2010-03-31 2011-10-06 주식회사 씨티씨바이오 올메사탄 실렉세틸의 제조 방법
WO2011155291A1 (fr) * 2010-06-09 2011-12-15 株式会社トクヤマ Procédé de préparation de candesartan cilexétil
WO2012055994A1 (fr) 2010-10-29 2012-05-03 Interquim, S.A. Procédé de préparation d'olmésartan médoxomil
WO2012055380A1 (fr) * 2010-10-29 2012-05-03 Zentiva, K. S. Procédé d'obtention d'olmésartan médoxomil
WO2013021312A1 (fr) * 2011-08-05 2013-02-14 Lupin Limited Procédé de préparation d'olmésartan médoxomil
CN103012382A (zh) * 2012-12-05 2013-04-03 威海迪之雅医药化工开发有限公司 一种奥美沙坦酯的制备方法
CN103304550A (zh) * 2012-03-16 2013-09-18 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
US8735598B2 (en) 2008-06-09 2014-05-27 Daiichi Sankyo Company, Limited Method for producing 1-biphenylmethylimidazole compound
US8859600B2 (en) 2009-04-28 2014-10-14 Daiichi Sankyo Company, Limited Acetone solvate crystals of trityl olmesartan medoxomil
US8933241B2 (en) 2009-04-28 2015-01-13 Daiichi Sankyo Company, Limited Method for producing olmesartan medoxomil
CN107311990B (zh) * 2017-07-25 2021-09-03 浙江华海致诚药业有限公司 一种奥美沙坦酯的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503785A1 (fr) * 1991-02-21 1992-09-16 Sankyo Company Limited Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique
WO2005021535A2 (fr) * 2003-08-27 2005-03-10 Zentiva, A.S. Procede d'extraction du groupe protecteur de triphenylmethane
WO2005111021A1 (fr) * 2004-05-05 2005-11-24 Teva Pharmaceutical Industries Ltd. Elaboration de of candesartan cilexetil de purete elevee

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503785A1 (fr) * 1991-02-21 1992-09-16 Sankyo Company Limited Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique
WO2005021535A2 (fr) * 2003-08-27 2005-03-10 Zentiva, A.S. Procede d'extraction du groupe protecteur de triphenylmethane
WO2005111021A1 (fr) * 2004-05-05 2005-11-24 Teva Pharmaceutical Industries Ltd. Elaboration de of candesartan cilexetil de purete elevee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
USIFOH C O: "Anticonvulsant activity of reaction products of 5,5-diphenylhydantoin with substituted methylene bromides", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 334, no. 11, 2001, pages 366 - 368, XP002319792, ISSN: 0365-6233 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735598B2 (en) 2008-06-09 2014-05-27 Daiichi Sankyo Company, Limited Method for producing 1-biphenylmethylimidazole compound
WO2010026255A1 (fr) * 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'un intermédiaire d'olmésartan médoxomil
US8933241B2 (en) 2009-04-28 2015-01-13 Daiichi Sankyo Company, Limited Method for producing olmesartan medoxomil
US8859600B2 (en) 2009-04-28 2014-10-14 Daiichi Sankyo Company, Limited Acetone solvate crystals of trityl olmesartan medoxomil
WO2010134052A1 (fr) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Procédé pour la préparation d'olmésartan médoxomil
WO2011007368A2 (fr) 2009-07-14 2011-01-20 Cadila Healthcare Limited Procédé amélioré de préparation d'olmésartan
KR20110109638A (ko) * 2010-03-31 2011-10-06 주식회사 씨티씨바이오 올메사탄 실렉세틸의 제조 방법
KR101628758B1 (ko) 2010-03-31 2016-06-09 주식회사 씨티씨바이오 올메사탄 실렉세틸의 제조 방법
WO2011155291A1 (fr) * 2010-06-09 2011-12-15 株式会社トクヤマ Procédé de préparation de candesartan cilexétil
JP5738288B2 (ja) * 2010-06-09 2015-06-24 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
WO2012055380A1 (fr) * 2010-10-29 2012-05-03 Zentiva, K. S. Procédé d'obtention d'olmésartan médoxomil
WO2012055994A1 (fr) 2010-10-29 2012-05-03 Interquim, S.A. Procédé de préparation d'olmésartan médoxomil
WO2013021312A1 (fr) * 2011-08-05 2013-02-14 Lupin Limited Procédé de préparation d'olmésartan médoxomil
US8981110B2 (en) 2011-08-05 2015-03-17 Lupin Limited Process for the preparation of olmesartan medoxomil
CN103304550A (zh) * 2012-03-16 2013-09-18 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN103012382A (zh) * 2012-12-05 2013-04-03 威海迪之雅医药化工开发有限公司 一种奥美沙坦酯的制备方法
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN107311990B (zh) * 2017-07-25 2021-09-03 浙江华海致诚药业有限公司 一种奥美沙坦酯的制备方法

Also Published As

Publication number Publication date
CZ299902B6 (cs) 2008-12-29
CZ2005679A3 (cs) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2007048361A1 (fr) Méthode d'élimination du groupement protecteur triphénylméthane de précurseurs de médicaments anti-hypertension
JP5685082B2 (ja) オルメサルタンメドキソミルの調製または精製の方法
US5578733A (en) Process for the production of tetrazolyl compounds
WO2007148344A2 (fr) Procédé de préparation d'olmésartan médoxomil
WO2012107814A1 (fr) Procédé amélioré pour la préparation d'azilsartan médoxomil
WO2007047838A2 (fr) Procede de preparation de l'olmesartan medoxomil
WO2014049512A2 (fr) Nouveau procédé de préparation d'azilsartan médoxomil
EP1658281A2 (fr) Procede d'extraction du groupe protecteur de triphenylmethane
WO2005051943A1 (fr) Procédés de préparation d'irbesartan très pur
WO2011007368A2 (fr) Procédé amélioré de préparation d'olmésartan
WO2005051929A1 (fr) Conversion de nitriles aromatiques en tetrazoles
BG107478A (bg) Метод за кристализация на лозартан калий
WO2012001694A1 (fr) Procédé de préparation d'olmésartan médoxomil
WO2010018441A2 (fr) Procédé amélioré pour la préparation de telmisartan sensiblement pur
KR101250820B1 (ko) 개선된 로사르탄 제조 방법
EP2170868A1 (fr) Procédé amélioré pour la préparation de candésartan cilexétil
US20080214637A1 (en) Process for the Synthesis of Tetrazoles
EP1984356A1 (fr) Procédé amélioré pour la préparation de candésartan cilexetil
KR101009404B1 (ko) (에스)-엔-(1-카르복시-2-메틸-프로-1-필)-엔-펜타노일-엔-[2'-(1에이취-테트라졸-5-일)비페닐-4-일-메틸]아민화합물의 고순도 제조방법
EP2022790A1 (fr) Procédé pour la préparation ou la purification d'olmésartan médoxomil
MX2007007303A (es) Proceso para preparar olmesartan medoxomil a ph superior a 2,5.
CZ2006173A3 (cs) Zpusob odstranování trifenylmethanové chránící skupiny u prekursoru antihypertensiv majících labilní, metabolicky odbouratelnou skupinu
WO2014027280A1 (fr) Procédé monotope pour la préparation de telmisartan
Dams et al. Supplementary Materials: Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
ES2264641A1 (es) Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06805257

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载